GeneTether Therapeutics Chairman Acquires 263% More Stock

Whilst it may not be a huge deal, we thought it was good to see that the GeneTether Therapeutics Inc. (CSE:GTTX) Chairman, Daren Graham, recently bought CA$128k worth of stock, for CA$0.02 per share. While that isn't the hugest buy, it actually boosted their shareholding by 263%, which is good to see.

See our latest analysis for GeneTether Therapeutics

GeneTether Therapeutics Insider Transactions Over The Last Year

Notably, that recent purchase by Daren Graham is the biggest insider purchase of GeneTether Therapeutics shares that we've seen in the last year. We do like to see buying, but this purchase was made at well below the current price of CA$0.12. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

GeneTether Therapeutics insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

Does GeneTether Therapeutics Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. GeneTether Therapeutics insiders own about CA$4.8m worth of shares (which is 103% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

So What Does This Data Suggest About GeneTether Therapeutics Insiders?

The recent insider purchases are heartening. We also take confidence from the longer term picture of insider transactions. But we don't feel the same about the fact the company is making losses. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about GeneTether Therapeutics. Nice! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing GeneTether Therapeutics. For example - GeneTether Therapeutics has 4 warning signs we think you should be aware of.

But note: GeneTether Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.